AC
CUE icon

Apogem Capital’s Cue Biopharma CUE Stock Holding History

Apogem Capital’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,687
Closed -$247K – 26
2022
Q3 		$247K Sell
3,687
-418
-10% -$36K 0.25% 107
2022
Q2 		$307K Buy
4,105
+396
+11% +$46.3K 0.28% 109
2022
Q1 		$543K Buy
3,709
+1,632
+79% +$346K 0.37% 90
2021
Q4 		$705K Buy
2,077
+351
+20% +$136K 0.46% 77
2021
Q3 		$754K Buy
1,726
+128
+8% +$44.6K 0.48% 84
2021
Q2 		$559K Buy
1,598
+175
+12% +$67.8K 0.36% 94
2021
Q1 		$521K Sell
1,423
-445
-24% -$183K 0.35% 92
2020
Q4 		$701K Buy
+1,868
New +$746K 0.47% 71

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Apogem Capital's CUE Position: Q4 2022 in Review

Apogem Capital sold out of Cue Biopharma (CUE) in Q4 2022, closing a stake of 3,687 shares — an estimated $247K sold.

Apogem Capital first reported a position in CUE in Q4 2020 and held it in 8 quarters. The position peaked at $754K in Q3 2021. 61 funds tracked by Wall St. Rank hold CUE as of Q4 2022.

  • Apogem Capital reported no remaining Cue Biopharma position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 3,687 Cue Biopharma shares in Q4 2022, an estimated $247K.
  • Apogem Capital first reported a position in Cue Biopharma in Q4 2020 and held it in 8 quarters.
  • Apogem Capital's Cue Biopharma position peaked at $754K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.